Merck to acquire Harpoon Therapeutics for $680m to strengthen oncology pipeline
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) have entered a definitive agreement where Merck will acquire Harpoon for $23 per share in cash, totaling an approximate equity value of $680 million. This strategic acquisition aims to bolster Merck’s oncology pipeline with Harpoon’s advanced cancer […]